Magnitude of Phenotypic and MTBDRplus Line Probe Assay First-Line Anti-Tuberculosis Drug Resistance Among Tuberculosis Patients; Northwest Ethiopia

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2021 Feb 19

PMID 33603414

Citations 6

Authors

Wubet Birhan Yigzaw

Jordi B Torrelles

Shu-Hua Wang

Belay Tessema

Affiliations

Soon will be listed here.

Abstract

Background: () drug resistance is a key challenge in ending TB.

Objective: The study aimed to determine anti-TB drug resistance and compare the discordance between phenotypic and genotypic drug-susceptibility testing (DST).

Methods: Prospective enrollment and sputum collection from patients suspected of active pulmonary TB from May 2018 to December 2019 at the University of Gondar Hospital. Phenotypic DST study for streptomycin, isoniazid, rifampin, and ethambutol was done by MGIT 360 SIRE Kit. Genotypic resistance for isoniazid and rifampin was performed by MTBDRplus v2 line probe assay (LPA) and compared to phenotypic drug resistance.

Results: A total of 376 patients, median age 32 years, and 53.7% male were enrolled. was isolated from 126 patients. 106/126 (84%) patients were newly diagnosed with TB and 20 patients with prior TB treatment. Seventy (66.0%) were susceptible to all anti-TB drugs tested. Twenty-five (19.8%) of the isolates were resistant to isoniazid, 12 (9.5%) to rifampicin and six (5%) were multidrug resistant. Among previously treated TB patients, 4 (20.0%) and 5 (25.0%) were mono-resistant and poly-resistant, respectively. The sensitivity and specificity of LPA resistance for isoniazid were 94.4% and 100%, and for rifampin was 75.0% and 100%, respectively.

Conclusion: The frequency of mono- and poly-drug resistance among both newly diagnosed and previously treated TB patients was high to the rest of the nation. MTBDRplus showed excellent concordance for isoniazid and rifampin. We concluded that DST should be performed for all patients to improve management and decrease spread of drug-resistant strains in the community.

Citing Articles

Drug resistance profiles of clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications.

Kangongwe M, Mwanza W, Mwamba M, Mwenya J, Muzyamba J, Mzyece J JAC Antimicrob Resist. 2024; 6(4):dlae122.

PMID: 39055721 PMC: 11271804. DOI: 10.1093/jacamr/dlae122.

Drug susceptibility testing and line probe assay of first-line anti-tuberculosis drugs among presumptive tuberculosis patients attending a secondary care hospital in Bhubaneswar.

Singh K, Barik B, Das S, Hussain T, Gupta B, Das D J Family Med Prim Care. 2024; 13(6):2491-2498.

PMID: 39027826 PMC: 11254078. DOI: 10.4103/jfmpc.jfmpc_736_23.

Molecular characterization of genetic mutations with fitness loss in pulmonary tuberculosis patients associated with HIV co-infection in Northwest Amhara, Ethiopia.

Seid A, Kassa M, Girma Y, Dereb E, Nureddin S, Abebe A SAGE Open Med. 2023; 11:20503121231208266.

PMID: 37933292 PMC: 10625730. DOI: 10.1177/20503121231208266.

Phenotypic and genotypic drug susceptibility patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Central and Southern Ethiopia.

Tilahun M, Wegayehu T, Wondale B, Gebresilase T, Gebreyohannes T, Tekola A PLoS One. 2023; 18(9):e0285063.

PMID: 37682820 PMC: 10491001. DOI: 10.1371/journal.pone.0285063.

Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia.

Seid A, Girma Y, Abebe A, Dereb E, Kassa M, Berhane N Infect Drug Resist. 2023; 16:3829-3845.

PMID: 37346368 PMC: 10281285. DOI: 10.2147/IDR.S412951.

References

Tessema B, Beer J, Emmrich F, Sack U, Rodloff A . First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis. 2012; 16(6):805-11. DOI: 10.5588/ijtld.11.0522. View

Jhun B, Koh W . Treatment of Isoniazid-Resistant Pulmonary Tuberculosis. Tuberc Respir Dis (Seoul). 2020; 83(1):20-30. PMC: 6953491. DOI: 10.4046/trd.2019.0065. View

Merker M, Kohl T, Barilar I, Andres S, Fowler P, Chryssanthou E . Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020; 12(1):27. PMC: 7060619. DOI: 10.1186/s13073-020-00726-5. View

Yakrus M, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B . Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States. Tuberc Res Treat. 2016; 2016:3404860. PMC: 4916310. DOI: 10.1155/2016/3404860. View

Kang J, Hur J, Kim S, Jeon S, Lee J, Kim Y . Clinical implications of discrepant results between genotypic MTBDR and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients. J Thorac Dis. 2019; 11(2):400-409. PMC: 6409268. DOI: 10.21037/jtd.2019.01.58. View

Flores-Trevino S, Morfin-Otero R, Rodriguez-Noriega E, Gonzalez-Diaz E, Perez-Gomez H, Mendoza-Olazaran S . Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico. Enferm Infecc Microbiol Clin. 2014; 33(3):181-5. DOI: 10.1016/j.eimc.2014.04.005. View

Nieto Ramirez L, Ferro B, Diaz G, Anthony R, de Beer J, van Soolingen D . Genetic profiling of Mycobacterium tuberculosis revealed "modern" Beijing strains linked to MDR-TB from Southwestern Colombia. PLoS One. 2020; 15(4):e0224908. PMC: 7182180. DOI: 10.1371/journal.pone.0224908. View

Abate D, Taye B, Abseno M, Biadgilign S . Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia. BMC Res Notes. 2012; 5:462. PMC: 3507648. DOI: 10.1186/1756-0500-5-462. View

Wondale B, Medhin G, Abebe G, Tolosa S, Mohammed T, Teklu T . Phenotypic and genotypic drug sensitivity of complex isolated from South Omo Zone, Southern Ethiopia. Infect Drug Resist. 2018; 11:1581-1589. PMC: 6161742. DOI: 10.2147/IDR.S165088. View

10.

Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B . Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017; 17(1):280. PMC: 5392973. DOI: 10.1186/s12879-017-2389-6. View

11.

Hirama T, Sabur N, Derkach P, McNamee J, Song H, Marras T . Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010-2016. Can Commun Dis Rep. 2020; 46(4):84-92. PMC: 7145431. DOI: 10.14745/ccdr.v46i04a05. View

12.

Torrea G, Ng K, Van Deun A, Andre E, Kaisergruber J, Ssengooba W . Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance. Sci Rep. 2019; 9(1):11826. PMC: 6694172. DOI: 10.1038/s41598-019-48401-z. View

13.

Mahomed S, Mlisana K, Cele L, Naidoo K . Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: Impact on bedside clinical decision making. J Clin Tuberc Other Mycobact Dis. 2020; 20:100176. PMC: 7414011. DOI: 10.1016/j.jctube.2020.100176. View

14.

Brhane M, Kebede A, Petros Y . Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist. 2017; 10:75-83. PMC: 5352243. DOI: 10.2147/IDR.S127903. View

15.

Edwards B, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D . Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017. PLoS One. 2020; 15(3):e0229691. PMC: 7064215. DOI: 10.1371/journal.pone.0229691. View

16.

Forson A, Kudzawu S, Kwara A, Flanigan T . High Frequency of First-Line Anti-Tuberculosis Drug Resistance among Persons with Chronic Pulmonary Tuberculosis at a Teaching Hospital Chest Clinic. Ghana Med J. 2011; 44(2):42-6. PMC: 2994151. DOI: 10.4314/gmj.v44i2.68858. View

17.

Kazemian H, Kardan-Yamchi J, Bahador A, Khonsari S, Nasehi M, Hamzehloo G . Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR. Infect Drug Resist. 2019; 12:3585-3593. PMC: 6863623. DOI: 10.2147/IDR.S222905. View

18.

Lobie T, Woldeamanuel Y, Asrat D, Beyene D, Bjoras M, Aseffa A . Genetic diversity and drug resistance pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in the Benishangul Gumuz region and its surroundings, Northwest Ethiopia. PLoS One. 2020; 15(4):e0231320. PMC: 7141659. DOI: 10.1371/journal.pone.0231320. View

19.

Swain S, Sharma D, Hussain T, Pati S . Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in . Emerg Microbes Infect. 2020; 9(1):1651-1663. PMC: 7473167. DOI: 10.1080/22221751.2020.1785334. View

20.

Haile B, Tafess K, Zewude A, Yenew B, Siu G, Ameni G . Spoligotyping and drug sensitivity of isolated from pulmonary tuberculosis patients in the Arsi Zone of southeastern Ethiopia. New Microbes New Infect. 2020; 33:100620. PMC: 6938991. DOI: 10.1016/j.nmni.2019.100620. View